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Genome-wide Association Study Identifies Multiple Risk Loci for 
Chronic Lymphocytic Leukemia
A full list of authors and affiliations appears at the end of the article.
Despite limited discovery stages (<1,125 cases), genome-wide association studies (GWAS) 
have successfully identified 13 loci associated with risk of chronic lymphocytic leukemia/
small lymphocytic lymphoma (CLL). To identify additional CLL susceptibility loci, we 
conducted the largest meta-analysis, to date, including four GWAS totaling 3,100 CLL cases 
and 7,667 controls with genotype data. In the meta-analysis, we discovered ten independent 
SNPs in nine novel loci at 10q23.31 (ACTA2/FAS; P=1.22×10−14), 18q21.33 (BCL2; 
P=7.76×10−11), 11p15.5 (C11orf21; P=2.15×10−10), 4q25 (LEF1; P=4.24×10−10), 2q33.1 
(CASP10/CASP8; P=2.50×10−9), 9p21.3 (CDKN2B-AS1; P=1.27×10−8), 18q21.32 
(PMAIP1; P=2.51×10−8), 15q15.1 (BMF; P=2.71×10−10), and 2p22.2 (QPCT; 
P=1.68×10−8) as well as an independent signal at an established locus (2q13, ACOXL, 
P=2.08×10−18). We also found evidence for two additional promising loci that reached 
marginal genome-wide significance (P<2.0×10−7) at 8q22.3 (ODF1; P=5.40×10−8) and 
5p15.33 (TERT; P=1.92×10−7). Although further studies are required, proximity of several 
of these loci to genes involved in apoptosis suggests a plausible underlying biological 
mechanism.
CLL is a B-cell malignancy with a strong familial component1 and an ~8.5-fold increased 
relative risk in first-degree relatives.2 Previous CLL GWAS have identified 13 loci that 
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explain a portion of the familial risk,3– 6 suggesting that additional loci of modest effects can 
be found using a larger discovery sample size.7
As part of a larger initiative in non-Hodgkin lymphoma (NHL) (called the NHL-GWAS), 
we genotyped 2,343 CLL cases and 2,854 controls of European descent from 22 studies 
using the Illumina OmniExpress Beadchip (see Online Methods and Supplementary Table 
1). Of those 5,197 subjects, 94% passed rigorous quality control criteria (see Online 
Methods and Supplementary Table 2) and 549,934 SNPs successfully passed quality control 
criteria with a median call rate >98%. We also utilized genotype data previously generated 
on the Illumina Omni2.5 from an additional 3,536 controls and one case from three studies8 
giving a total of 2,179 cases and 6,221 controls for the analysis of the NHL-GWAS 
(Supplementary Table 3).
In the NHL-GWAS (Stage 1) analysis, we observed an enrichment of SNPs with small P-
values compared to the null distribution with a lambda of 1.026 in the Q-Q plot 
(Supplementary Figure 1). After exclusion of previously established loci, an excess of small 
P-values still remained suggesting additional novel loci were yet to be discovered. In our 
Stage 1 analyses, we observed SNPs from 10 unique loci (defined as separated by at least 
500kb and linkage disequilibrium (LD) r2<0.05), which reached genome-wide significance 
(P<5×10−8), including eight established loci and two novel loci (Supplementary Figure 2).
We then performed a meta-analysis of the NHL-GWAS with three other independent CLL 
GWAS5,9 that had a combined total of 921 CLL cases and 1,446 controls (Stage 2, 
Supplementary Tables 1 and 3). Because these other CLL GWAS studies were conducted on 
different commercial SNP microarrays, we imputed common SNPs from the 1000 Genomes 
Project10 using IMPUTE211 (Online Methods, Supplementary Table 4). In the meta-
analysis of stages 1 and 2 data, associations for all 13 established loci showed a consistent 
direction of effect with previously reported studies, and 10 loci achieved P<5×10−8 
(Supplementary Table 5). However, two previously established loci, 15q25.2 and 19q13.3, 
were only nominally significant in the meta-analysis (P=0.03, and P=0.008, respectively), 
and no significant association was observed in stage 1 for the 15q25.2 locus (P=0.10). A 
suggestive locus on 18q21.1 that had not met genome-wide significance in prior studies12 
was also nominally significant (P=5.06×10−4) herein. From the meta-analysis of stages 1– 2, 
we identified 10 promising SNPs in the eight novel loci and one promising SNP in an 
established locus that we carried forward for a de novo replication in stage 3: this included 
an additional 392 cases and 4561 controls and in silico replication in an independent CLL 
GWAS with 396 cases and 311 controls (see Online Methods and Supplementary Tables 1, 
3, and 4).
Seven of the 10 SNPs in novel loci reached genome-wide significance in the meta-analysis 
of all three stages: 10q23.31 (ACTA2/FAS; P=1.22×10−14), 18q21.33 (BCL2; 
P=2.66×10−12), 11p15.5 (C11orf21; P=2.15×10−10), 4q25 (LEF1; P=4.24×10−10), 2q33.1 
(CASP10/CASP8; P=2.50×10−9), 9p21.3 (CDKN2B-AS1; P=1.27×10−8), and 18q21.32 
(PMAIP1; P=2.51×10−8) (Table 1, Figure 1). Further, within the 18q21.33 locus, a second 
SNP (rs4987852) in low LD (r2=0.01) with rs4987855 and located only 372 bp away, also 
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reached genome-wide significance (Table 1, P =7.76×10−11); this SNP was determined to be 
independent in conditional analyses (Pconditional =3.87×10−7, Table 2).
To explore these regions in greater detail and identify additional loci that we may have 
missed using just the genotyped SNPs in Stage 1, we imputed Stage 1 of our NHL-GWAS 
using the 1000 Genomes Project10 data (February 2012 release) and performed a meta-
analysis of the results from stage 1 and stage 2. The most significant SNPs at three of our 
novel loci, 10q23.31 (rs2147420) 18q21.33 (rs4987856), and 4q25 (rs2003869), were highly 
correlated (r2 ≥0.95) with our strongest genotyped SNPs, rs4406737, rs4987885, and 
rs898518, respectively (Supplementary Table 6). Only modest correlation (r2 range: 0.18–
0.58) was observed for the most significant imputed SNPs at 11p15.5 (rs2521269), 2q33.1 
(rs11688943), and 9p21.3 (rs1359742) and our strongest genotyped SNPs in each of the 
respective regions. The most significant of the imputed SNPs at 18q21.32 (rs35748167) 
appeared to be independent of our strongest genotyped SNP (rs4368253, r2=0.003, 
Pconditional < 7.89×10−7 for both SNPs), suggesting a possible second, independent signal 
(Table 2).
Meta-analysis of our imputed scan data revealed two novel loci, 15q15.1 (BMF; 
P=2.71×10−10) and 2p22.2 (QPCT; P=1.68×10−8) (Table 1, Figure 1). In addition, although 
our genotyped SNP at 5p15.33 (TERT, rs10069690, P=1.92×10−7) (Supplementary Table 7) 
did not reach genome-wide significance, we did observe an imputed SNP in this region that 
reached genome-wide significance (rs7705526; P=3.75×10−8). Another promising locus was 
observed at 8q22.3 (ODF1; P=5.40×10−8) (Supplementary Table 7). Additional studies are 
needed to confirm these findings, particularly the signal on 5p15.33, which is already known 
to harbor risk variants for multiple cancers.13– 20,
An examination of established loci revealed a new SNP in 2q13 (BCL2L11, rs13401811, 
P=6.09×10−17; Table 1, Figure 2) that was independent of the previously reported SNP. 
After conditioning on the established 2q13 SNP (rs17483466, r2=0.02), the new SNP 
rs13401811 remained strongly associated with CLL risk (Pconditional=1.60×10−12, Table 2). 
A putative second signal was observed at the established 2q37.3 locus (Supplementary Table 
5, rs7578199, P =5.39×10−7) that was in low LD (r2=0.01) and independent of the 
previously reported rs757978 SNP (Pconditional=6.10×10−6, Table 2), although rs7578199 
was not genome-wide significant. Another possible second signal was observed on 6p21.32 
(Supplementary Table 5, HLA, rs9273363, P=2.24×10−10). Rs9273363 showed some 
evidence of conditional independence with the originally reported SNPs (r2≤0.25, Pconditional 
≤3.50×10−9, Table 2); however, it may be part of a shared HLA haplotype; thus accurate 
HLA typing is needed to further clarify its level of independence. Finally, we observed a 
SNP at 15q21.3 (Supplementary Table 5, rs11636802, P=1.68×10−13) that had stronger 
statistical significance than that of the previously reported SNP, rs7169431 (P=1.72×10−05). 
Although only modestly correlated (r2=0.16), rs11636802 explained all of the risk 
associated with rs7169431 in a conditional analysis (Table 2) suggesting that this SNP may 
be a better marker for the locus.
Heritability analysis indicated that the ten independent SNPs in our novel loci together with 
the new independent SNP at 2q13 (Table 1) explain approximately 5% more of the familial 
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risk in addition to ~12% for the established loci. When we explored the contribution of all 
common variants to the genetic heritability of CLL (using a method that estimates the 
variance explained by fitting all genotyped autosomal SNPs simultaneously21,22, Online 
Methods) 21,22 21,22 we estimate that common SNPs have the potential to explain up to 
~46% of the familial risk, suggesting more common loci, likely of small effects, are still yet 
to be discovered. However, the analysis also implies that common SNPs probably do not 
explain all of the familial risk and other factors, such as uncommon SNPs with modest 
effects or rare highly penetrant variants, are likely to also play a role.
Five of the novel loci (10q23.31, 18q21.33, 2q33.1, 18q21.32, and 15q15.1) identified in 
this study as well as the new SNP at the established 2q13 locus are located in or near genes 
involved in apoptosis. Rs4406737 is located on 10q23.31 between the first and second exons 
of FAS, a member of the tumor necrosis factor receptor superfamily that has a crucial role in 
the initiation of the signaling cascade of the caspase family in apoptosis. Mutations in FAS 
leading to defective Fas-mediated apoptosis have been documented in inherited 
lymphoproliferative disorders associated with autoimmunity,23,24 and families with 
germline FAS mutations have a substantially increased risk of other lymphoma subtypes.25
The two newly identified SNPs at 18q21.33 (rs4987855 and rs4987852) map to the 3̘-UTR 
of B-cell CLL/lymphoma 2 (BCL2), which encodes an essential outer mitochondrial 
membrane protein that blocks lymphocyte apoptosis. Constitutive expression of BCL2 
through t(14:18) and other translocations is common in follicular lymphomas, but the 
translocation is also seen in CLL albeit rarely.26 Both SNPs are located within a narrow 
region of BCL2 where the majority of t(14;18) translocation breakpoints occur.27 rs4987855 
is in linkage disequilibrium with a SNP (rs4987856, r2=1.0) that is located within 200bp of a 
putative microRNA binding site for mir-19528 and was found to be nominally correlated 
with BCL2 expression (Supplementary Table 8, P=0.02)29. Forced overexpression of BCL2 
in mice leads to an increased incidence of B-cell lymphomas.30
The novel SNPs at 18q21.32 and 15q15.1 as well as the new SNP at the established 2q13 
locus are located near Bcl-2 family member genes. Rs4368253 is located approximately 
51kb downstream from phorbol-12-myristat-13-acetate-induced protein 1 (PMAIP1), which 
encodes the proapoptotic BCL2 protein, NOXA. Regulation of apoptosis through NOXA is 
critical for B-cell expansion after antigen triggering.31 Down-regulation of NOXA 
contributes to the persistence of CLL B-cells in the lymph node environment.32 Rs8024033 
is located approximately 5.4kb upstream of Bcl-2 modifying factor (BMF), which encodes 
an apoptotic activator that binds to BCL2 proteins. BMF has been implicated in the survival 
of chronic lymphocytic leukemia cells33, and loss of BMF in mice leads to B-cell 
hyperplasia and an accelerated development of radiation-induced thymic lymphomas34. The 
new SNP (rs13401811) at 2q13, a locus previously implicated in risk of CLL3,35,36 and 
more generally B-cell non-Hodgkin lymphomas,37 is located approximately 262kb upstream 
of BCL2-like 11 (BCL2L11). BCL2L11 encodes a pro-apoptotic member of the BCL2 
family, BIM, which plays a key role in the regulation of apoptosis in T- and B-cell 
homeostasis. Loss of BIM accelerates Myc-induced leukemia in mice,38 and this SNP has 
been previously reported to be nominally associated with CLL in a small candidate gene 
study.39
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The novel 2q33.1 SNP (rs3769825) resides in intron 2 of caspase-8 (CASP8) and is in LD 
with a missense SNP (rs13006529, r2=0.71) in the nearby caspase-10 (CASP10) 
(Supplementary Table 9), both of which play a central role in cell apoptosis. SNPs within 
this region have been associated with breast cancer,40 esophageal cancer,41 and melanoma42 
susceptibility. SNPs in CASP8/CASP10, including one in moderate LD with ours 
(rs11674246, r2=0.66), were previously nominally associated with CLL risk in smaller case-
control studies.43,44
The remaining four novel loci (11p15.5, 4q25, 9p21.3 and 2p22.2) map to other biologically 
interesting genes. The 4q25 SNP, rs898518, is located between the fourth and fifth exons of 
lymphoid enhancer-binding factor 1 (LEF1), which encodes a transcription factor involved 
in the Wnt signaling pathway, an essential component for the normal homeostasis of 
hematopoietic stem cells.45 Aberrant protein expression of LEF1 has been observed in CLL 
cells as well as monoclonal B-cell lymphocytosis, suggesting that LEF1 plays an early role 
in CLL leukemogenesis.46 Rs1679013 maps to an inter-genic region on 9p21.3, roughly 
200kb upstream fromCDKN2B-AS1, an antisense non-coding RNA implicated in the risk of 
acute lymphocytic leukemia.47 The 2p22.2 SNP (rs3770745) is located approximately 52kb 
upstream of protein kinase D3 (PRKD3), which interacts with transcriptional repressor, B-
cell lymphoma 6 (BCL-6). Lastly, the 11p15.5 region contains many imprinted genes and 
has been implicated in Beckwith-Wiedemann syndrome,48 a disorder characterized by 
excessive growth and a high incidence of childhood tumors.49
In conclusion, our large GWAS of CLL identified ten SNPs in nine novel loci and one new 
independent SNP in a previously discovered locus. Together with the previously established 
loci, the cumulative set of SNPs correspond to an area-under-the-curve (AUC) of 0.73. 
Although further studies are required to fine-map the regions, the proximity of several of 
these loci to genes involved in apoptosis suggests a possible underlying mechanism of 
biological relevance. Our results further support a substantial contribution of common gene 
variants in the pathogenesis of CLL.
ONLINE METHODS
Stage 1: NHL-GWAS
As part of a larger initiative, we conducted a genome-wide association study (GWAS) of 
CLL using cases and controls of European descent from 22 studies of non-Hodgkin 
lymphoma (NHL) (Supplementary Table 1), including nine prospective cohort studies, eight 
population-based case-control studies, and five clinic or hospital-based case-control studies. 
All studies obtained informed consent from their participants and approval from their 
respective Institutional Review Boards for this study. As described in Supplementary Table 
1, cases were ascertained from cancer registries, clinics or hospitals, or through self-report 
verified by medical and pathology reports. The phenotype information for all NHL cases 
was reviewed centrally at the International Lymphoma Epidemiology Consortium 
(InterLymph) Data Coordinating Center and harmonized according to the hierarchical 
classification proposed by the InterLymph Pathology Working Group based on the World 
Health Organization (WHO) classification (2008).50,51
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All CLL cases with sufficient DNA (n=2,343) and a subset of available controls frequency-
matched by age and sex to cases (n=2,854) including 4% quality control duplicates were 
genotyped on the Illumina OmniExpress at the NCI Cancer Genomic Research Laboratory 
(CGR). Genotypes were called using Illumina GenomeStudio software, and quality control 
duplicates showed >99% concordance. Extensive quality control metrics were applied to the 
data. Monomorphic SNPs and SNPs with a call rate <93% were excluded. Samples with a 
call rate ≤93%, mean heterozygosity <0.25 or >0.33 based on the autosomal SNPs, or 
gender discordance (>5% heterozygosity on X chromosome for males and <20% 
heterozygosity on the X chromosome for females) were excluded. Unexpected duplicates 
(>99.9% concordance) and first-degree relatives based on identity by descent (IBD) sharing 
with Pi-hat>0.40 were removed. Ancestry was assessed using the GLU struct.admix module 
based on the method proposed by Pritchard et al,52 and participants with <80% European 
ancestry were excluded (Supplementary Figure 3). After exclusions, 2,178 (93%) cases and 
2,685 (94%) controls remained (Supplementary Table 2). Genotype data previously 
generated on the Illumina Omni2.5 from additional 3,536 controls and 1 case from three of 
the studies (ATBC, CPSII, and PLCO) were also included,8 resulting in a total of 2,179 
cases and 6,221 controls for the stage 1 analysis. Of these additional controls, 703 (~235 
from each study) were selected to be representative of their cohort and cancer-free8. The 
remaining 2,823 controls were cancer-free controls from an unpublished study of prostate 
cancer in PLCO. SNPs with call rate <99%, with Hardy-Weinberg equilibrium P-
value<1×10−6 or minor allele frequency <1% were excluded from analysis, leaving 549,934 
SNPs for analysis. To evaluate population substructure, a principal components analysis 
(PCA) was performed using the Genotyping Library and Utilities (GLU), version 1.0, 
struct.pca module, which is similar to EIGENSTRAT.53 Plots of the first ten principal 
components are shown in Supplementary Figure 4. Association testing was conducted 
assuming a log-additive genetic model, adjusting for age, sex, and significant principal 
components. All data analysis and management was conducted using GLU.
Stage 2: Three Independent CLL GWAS
Three independent CLL GWAS provided genotype data for a meta-analysis (Supplementary 
Table 1). In all three studies, subjects with a genotyping call rate <95%, duplicates, related 
individuals, and SNPs with a call rate <95% were removed prior to imputation 
(Supplementary Table 4). Imputation was conducted separately for each study using 
IMPUTE211 and a hybrid of the 1000 Genomes Project version 2 (February 2012 release) 
and Division of Cancer Epidemiology and Genetics (DCEG) European reference panels.8,10 
SNPs were imputed for a total of 921 cases and 1446 controls. Association testing was 
conducted for each study using SNPTEST version 2, adjusting for age, sex, and significant 
principal components for GEC and UCSF2. No principal components were significant for 
the Utah study.
Stage 3: Replication studies and technical validation
In stage 3, 10 SNPs in the most promising loci and one SNP from an established locus were 
taken forward for de novo replication in an additional 392 cases and 4561 controls from the 
NCI replication study (NCI Rep) and from the Utah/Sheffield Chronic Lymphocytic 
Leukemia study (Utah-Sheffield) (Supplementary Table 1). Additionally, these 10 SNPs 
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were also taken forward in an in silico replication in 396 CLL cases and 311 controls from 
the International Cancer Genome Consortium (ICGC) (Supplementary Table 1). Genotyping 
for the NCI Rep study was conducted using custom TaqMan genotyping assays (Applied 
Biosystems) at the NCI Core Genotyping Resource and genotyping for the Utah-Sheffield 
study was conducted at the Core Research Facilities at the University of Utah. Blind 
duplicates (~5%) yielded 100% concordance. The ICGC study provided results for eight 
SNPs (or proxies) that were genotyped on the Affymetrix 6.0 SNP microarray 
(Supplementary Table 4). Association results for the NCI Rep and Utah-Sheffield studies 
were adjusted for age and sex, and results from the ICGC were adjusted for age, sex, and 
significant principal components. A comparison of the genotyping calls from the 
OmniExpress microarray and confirmatory TaqMan assays (n=384) yielded 99.9% 
concordance.
Meta analysis
Meta-analyses were performed using the fixed effects inverse variance method based on the 
beta estimates and standard errors from each study. For all SNPs in Tables 1 and 2, no 
substantial heterogeneity was observed among studies in stage 1 or among studies in stages 
1– 3 combined after Bonferroni correction (Pheterogeneity ≥ 0.02 for all SNPs).
Further follow-up analyses
Using 1000 Genomes data, we identified SNPs with r2>0.7 with our lead SNP that were 
reported to be non-synonymous or nonsense variants. We utilized HaploReg54 which is a 
tool for exploring non-coding functional annotation using ENCODE data, to evaluate the 
genome surrounding our SNPs (Supplementary Table 9). In addition, we evaluated cis 
associations between all novel and promising SNPs discovered in this study and the 
expression of nearby genes in lymphoblastoid cell lines from subjects of European descent 
from three publically available datasets29,55,56 (Supplementary Table 8).
Heritability analyses
To evaluate the familial risk explained by the novel loci identified in this study, we 
estimated the contribution of each SNP to the heritability using the equation7, 
h2SNP=Ś22f(1−f), where Ś is the log-odds ratio per copy of the risk allele and f is the allele 
frequency, and then summed the contributions of all novel SNPs. Using the equation derived 
by Pharoah et al57 to estimate the total heritability from the sibling relative risk (RR=8.5 
from Goldin et al2), we then calculated the proportion of familial risk explained by dividing 
the summed contributions of the novel SNPs by the total heritability.
To estimate the contribution of all common SNPs to familial risk, we used the method 
proposed by Yang et al21, (which was extended to dichotomous traits22 and implemented in 
the Genome-wide Complex Trait Analysis (GCTA) software.58 The genetic similarity 
matrix was estimated from our discovery scan using all genotyped autosomal SNPs with a 
minor allele frequency >0.01. We used restricted maximum likelihood (REML), the default 
option for GCTA, to fit the appropriate variance components model that included the top 10 
eigenvectors as covariates. The final estimate of heritability on the underlying liability scale 
assumed that the lifetime risk of CLL was 0.005. From this estimate, we calculated the 
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proportion of familial risk explained based on a familial relative risk of 8.5. Details of fitting 
the variance components model and transforming from the observed to liability scale have 
been previously documented.22
Estimate of recombination hotspots
To identify recombination hotspots in the region we used SequenceLDhot59, a program that 
uses the approximate marginal likelihood method60 and calculates likelihood ratio statistics 
at a set of possible hotspots. We tested five unique sets of 100 control samples. PHASE v2.1 
program was used to calculate background recombination rates61,62 and LD heatmap was 
visualized in r2 using snp.plotter program.63
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Figure 1. Association results, recombination hot-spots, and linkage disequilibrium (LD) plots for 
the regions newly associated with CLL
Top, association results of GWAS data from Stage 1 NHL-GWAS (grey diamonds), Stage 2 
combined data (blue diamond), Stage 3 combined data (purple diamond), and Stages 1– 3 
combined data (red diamond) are shown in the top panel with −log10(P) values (left y axis). 
Overlaid are the likelihood ratio statistics (right y axis) to estimate putative recombination 
hotspots across the region on the basis of 5 unique sets of 100 randomly selected control 
samples. Bottom, LD heatmap based on r2 values from total control populations for all SNPs 
included in the GWAS. (a) 10q23.31 region; (b) 18q21.33 region; (c) 11p15.5 region; (d) 
4q25 region; (e) 2q33.1 region; (f) 9p21.3 region; (g) 18q21.32 region; (h) 15q15.1 region; 
(i) 2p22.2 region.
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Figure 2. Association results, recombination hot-spots, and linkage disequilibrium (LD) plot for 
the new independent CLL susceptibility SNP in the 2q13 established locus
Top, association results of GWAS data from Stage 1 NHL-GWAS (grey diamonds), Stage 2 
combined data (blue diamond), Stage 3 combined data (purple diamond), and Stages 1– 3 
combined data (red diamond) are shown in the top panel with −log10(P) values (left y axis). 
Overlaid are the likelihood ratio statistics (right y axis) to estimate putative recombination 
hotspots across the region on the basis of 5 unique sets of 100 randomly selected control 
samples. Bottom, LD heatmap based on r2 values from total control populations for all SNPs 
included in the GWAS.
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Table 1
Association results for novel loci and new independent SNPs
Chr Nearest gene(s) SNP
Risk Other
pPosition allelea allele RAF Stage OR (95% CI)
Novel loci
10q23.31 ACTA2, FAS rs 4406737 90,749,704 G A 0.57 Stage 1 1.30 (1.21– 1.40) 3.30 × 10−12
Stage 2 1.17 (1.03– 1.32) 0.01
Stage 3 1.27 (1.06– 1.52) 0.007
Combinedb 1.27 (1.19–1.33) 1.22 × 10−14
18q21.33 BCL2 rs4987855* 58,944,529 G A 0.91 Stage 1 1.47 (1.28– 1.69) 5.51 × 10−8
Stage 2 1.47 (1.18– 1.85) 0.0007
Stage 3 1.43 (1.12– 1.82) 0.004
Combinedb 1.47 (1.32–1.61) 2.66 × 10−12
rs 4987852 58,944,901 G A 0.06 Stage 1 1.43 (1.26– 1.63) 2.67×10−8
Stage 2 1.24 (0.98– 1.56) 0.07
Stage 3 1.52 (1.17– 1.97) 0.002
Combinedb 1.41 (1.27–1.56) 7.76 × 10−11
11p15.5 C11orf21, TSPAN32 rs 7944004 2,267,728 T G 0.49 Stage 1 1.19 (1.11– 1.28) 7.20×10−7
Stage 2 1.15 (1.02– 1.32) 0.03
Stage 3 1.27 (1.11– 1.45) 0.0006
Combinedb 1.20 (1.13–1.27) 2.15 × 10−10
4q25 LEF1 rs898518* 109,236,273 A C 0.59 Stage 1 1.16 (1.08– 1.24) 8.47×10−5
Stage 2 1.26 (1.11– 1.43) 0.0004
Stage 3 1.30 (1.14– 1.49) 0.0002
Combinedb 1.20 (1.14–1.27) 4.24 × 10−10
2q33.1 CASP10, CASP8 rs 3769825 201,819,625 T C 0.45 Stage 1 1.18 (1.10– 1.27) 3.43×10−6
Stage 2 1.16 (1.03– 1.32) 0.01
Stage 3 1.22 (1.07– 1.40) 0.004
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Chr Nearest gene(s) SNP
Risk Other
pPosition allelea allele RAF Stage OR (95% CI)
Combinedb 1.19 (1.12–1.25) 2.50 × 10−9
9p21.3 CDKN2B-AS1 rs 1679013 22,196,987 C T 0.52 Stage 1 1.18 (1.10– 1.27) 4.47×10−6
Stage 2 1.32 (1.12– 1.52) 0.0004
Stage 3 1.11 (0.93– 1.32) 0.25
Combinedb 1.19 (1.12–1.27) 1.27 × 10−8
18q21.32 PMAIP1 rs 4368253 55,773,267 C T 0.69 Stage 1 1.18 (1.09– 1.27) 3.65×10−5
Stage 2 1.24 (1.08– 1.41) 0.002
Stage 3 1.18 (1.02– 1.37) 0.03
Combinedb 1.19 (1.12–1.27) 2.51 × 10−8
15q15.1 BMF rs8024033† 38,190,949 C G 0.51 Stage 1 1.22 (1.14– 1.32) 2.72×10−8
Stage 2 1.22 (1.08– 1.39) 0.003
Stage 3 - -
Combinedb 1.22 (1.15–1.30) 2.71 × 10−10
2p22.2 QPCT, PRKD3 rs3770745† 37,449,593 T C 0.22 Stage 1 1.29 (1.18– 1.40) 8.23×10−9
Stage 2 1.10 (0.95– 1.28) 0.21
Stage 3 - -
Combinedb 1.24 (1.15–1.33) 1.68 × 10−8
New independent SNP in established locus
2q13 ACOXL, BCL2L11 rs13401811* 111,332,575 G A 0.81 Stage 1 1.43 (1.28– 1.56) 9.76×10−13
Stage 2 1.45 (1.23– 1.72) 9.39×10−6
Stage 3 1.32 (1.08– 1.59) 0.007
Combinedb 1.41 (1.30–1.52) 2.08 × 10−18
a
The risk allele is the allele corresponding to the estimated odds ratio; RAF= risk allele frequency in controls; OR= per allele odds ratio adjusted for age, sex and significant principal components.
bNumber of cases and controls in the joint analysis of stage 1+stage2+stage3: rs4406737 (3,481/12,170), 20 rs4987855 (3,883/12,446), rs4987852 (3,880/12,497), rs7944004 (3,869/12,476), rs898518 
(3,879/12,441), rs3769825 (3,885/12,471), rs1679013 (3,482/12,148), rs4368253 (3,882/12,473), rs8024033 (3096/7663), rs3770745 (3097/7663), rs13401811 (3,839/12,264).
*
For the ICGC study in stage 3, results for proxy SNPs were provided (rs4987856/rs4987855, r2=1.0; rs7698317/rs898518, r2=1.0; rs1554005/rs13401811, r2=1.0).
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†
Identified from the 1000 Genomes meta-analysis of stage 1 and stage 2 with imputation information >0.9 in the NHL-GWAS.
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Table 2
Conditional analyses for select SNPs
New SNP Chr Position Nearest gene ORa Pa
Conditional Conditional Established
r2 * ORc Pc
Conditional Conditional
ORb Pb SNP ORd Pd
rs13401811 2q13 111,332,575 ACOXL, BCL2L11 1.43 6.09×10−17 1.35 1.60×10−12 rs17483466 0.02 1.37 3.53×10−17 1.31 6.70×10−13
rs7578199 2q37.3 241,841,521 HDLBP, FARP2 1.20 5.39×10−7 1.19 6.10×10−6 rs757978 0.01 1.29 1.35×10−7 1.26 2.37×10−6
rs9273363 6p21.32 32,734,250 HLA 1.24 2.24×10−10 1.24 3.50×10−9 rs674313 0.21 1.13 5.00×10−4 1.06 0.11
rs9273363 6p21.32 32,734,250 HLA 1.24 2.24×10−10 1.23 3.14×10−9 rs9272535 0.11 1.18 7.60×10−6 1.12 0.002
rs11636802 15q21.3 54,562,889 MNS1 1.41 1.68×10−13 1.38 1.54×10−9 rs7169431 0.16 1.27 1.72×10−5 1.06 0.32
rs35748167 18q21.32 56,188,413 PMAIP1, MC4R 1.32 9.31×10−9 1.25 7.89×10−7 rs4368253e 0.003 1.19 2.82×10−7 1.18 5.76×10−7
rs4987852 18q21.33 58,944,901 BCL2 1.41 7.76×10−11 1.36 1.50×10−8 rs4987855e 0.01 1.47 2.66×10−12 1.41 1.33×10−10
*
r2 linkage disequilibrium is based on 1000 Genomes Project and is between the new SNP and established SNP in the locus
aOR per allele odds ratio and P for the new SNP from the unconditional meta-analysis based on stage 1 + 2 for all loci, except 18q21.33. Data from stages 1– 3 was used for 18q21.33.
bOR and P for the new SNP from the conditional meta-analysis
cOR and P for the established SNP from the unconditional meta-analysis
dOR and P for the established SNP from the conditional meta-analysis
eSNP discovered and confirmed in the current study
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